We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

For Swiss policymakers confronting the franc’s strongest levels in almost a decade, there’s comfort to be had: its squeeze on ...